Meb Keflezighi, one of the world's best runners, joined Lee University and ran in the 65 Roses 5K in Cleveland, Tenn. to support the fight against cystic fibrosis. Lee University was thrilled to welcome him as part of its longstanding tradition of raising funds in support of the CF Foundation's mission.
Site Search
PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Vestavia Hills High School Raises More than $17,000 and Beats Schools Nationwide
Bill Would Remove Financial Penalties for Participating in Research Studies
CFF-Championed Bill Eliminates Barriers to Participation in Clinical Trials for People with CF and other Rare Diseases
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.
Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.